Celltrion Pharm Q1 2026 Provisional Results: Sales +17.4% YoY, Operating Profit +20.2%
-
Q1 2026 (Jan-Mar) provisional individual results: Sales KRW 132.1bn (QoQ -14.4%, YoY +17.4%)
-
Operating profit KRW 12.9bn (QoQ -6.0%, YoY +20.2%)
-
Net income KRW 8.8bn (QoQ -0.7%, YoY +20.4%)
-
Profit before tax KRW 11.8bn (QoQ +12.7%, YoY +24.7%)
-
These are preliminary internal figures, subject to change after external audit
KOSDAQ Filing Information
-
Filing: Preliminary Operating Results (Fair Disclosure)
-
Company: Celltrion Pharm (068760)
-
Submission: Celltrion Pharm Inc.
-
Receipt: 05-06-2026
-
Under KRX KOSDAQ Market Division